The Experts below are selected from a list of 261 Experts worldwide ranked by ideXlab platform

J Ferguson - One of the best experts on this subject based on the ideXlab platform.

  • The management of idiopathic Solar Urticaria
    Journal of Dermatological Treatment, 2009
    Co-Authors: D Bilsland, J Ferguson
    Abstract:

    The management of Solar Urticaria varies with clinical severity. For many, non-sedative antihistamine will produce a significant improvement, particularly when used in conjunction with an appropriate sunscreen. A phototherapy or photochemotherapy desensitization programme is frequently helpful. In resistant cases hydroxychloroquine or, if severe, plasmapheresis may be worth a trial.

  • Solar Urticaria: 40 Cases Reviewed from Japan
    NEJM Journal Watch, 2000
    Co-Authors: J Ferguson
    Abstract:

    Solar Urticaria is an uncommon disorder that can cause anaphylaxis and death. The idiopathic form of Solar Urticaria is diagnosed when endogenous

  • prolonged benefit following ultraviolet a phototherapy for Solar Urticaria
    British Journal of Dermatology, 1997
    Co-Authors: R S Dawe, J Ferguson
    Abstract:

    Summary Two patients with severe idiopathic Solar Urticaria, previously resistant to a variety of therapies including plasma exchange, benefited from springtime courses of ultraviolet A (UVA) monotherapy. Sites which are normally exposed to sunlight were treated, in a cabinet fitted with Philips R-UVA lamps (emitting UVA and visible wavelengths, with peak at 350 nm), twice daily for 2–3 weeks. One patient has been treated in this way for 3, and the other for 2, consecutive years. Repeat monochromator phototesting 3 months after their latest courses of UVA showed a persistent reduction in severity of abnormal photosensitivity. Both patients describe a sustained improvement in their condition lasting over 6 months after treatment.

  • plasma exchange therapy for Solar Urticaria
    British Journal of Dermatology, 1996
    Co-Authors: P Collins, R Ahamat, C Green, J Ferguson
    Abstract:

    Summary We report two cases of severe idiopathic Solar Urticaria treated.1 with plasma exchange therapy. Previous treatment which included antihistamines and. in one patient, desensitization with psoralens and ultraviolet A (PUVA) and narrowband ultraviolet B phototherapy produced only partial benefit. The effect of plasma exchange therapy was assessed using monochromator phototesting and intradermal injection of in vitro irradiated serum. One patient responded but relapsed within 2 weeks. We have failed to demonstrate a lasting benefit from plasma exchange therapy (PExT) in the treatment of two patients with idiopathic Solar Urticaria.

  • a comparison of cetirizine and terfenadine in the management of Solar Urticaria
    Photodermatology Photoimmunology and Photomedicine, 1991
    Co-Authors: D Bilsland, J Ferguson
    Abstract:

    : Many Solar Urticaria patients may benefit from the use of antihistamines. Historically, the value of such therapy was limited by sedation. Newer agents such as terfenadine and cetirizine that are relatively non-sedating appear to be better tolerated by patients. The latter drug, in addition to its antihistamine effect, also appears to inhibit eosinophil migration, which terfenadine and other potent H1 antagonists do not significantly affect. Eosinophils have been reported as early migrating cells in induced Solar Urticaria, raising the possibility that the dual action of cetirizine may provide a greater potential benefit in the management of Solar Urticaria. Six patients with idiopathic Solar Urticaria were entered into a double-blind, phototest study to compare cetirizine and terfenadine. Using the minimal Urticarial dose as a phototest end-point, both drugs were equally effective in raising the threshold of sensitivity in 4 patients. Two patients failed to respond to either therapy, which is in keeping with the known variable response to histamine blockade in Solar Urticaria. At the dosage used, cetirizine therapy appears to be no more effective than terfenadine.

T Schwarz - One of the best experts on this subject based on the ideXlab platform.

  • uva rush hardening for the treatment of Solar Urticaria
    Journal of The American Academy of Dermatology, 2000
    Co-Authors: Stefan Beissert, Hartmut Stander, T Schwarz
    Abstract:

    Abstract Induction of tolerance by subsequent UV exposures is the most effective therapy for Solar Urticaria; however, it is time-consuming and takes a long time until protection is achieved. Three patients with Solar Urticaria were exposed to multiple UVA irradiations at 1-hour intervals per day. With this rush hardening regimen, protection was achieved within 3 days. (J Am Acad Dermatol 2000;42:1030–2.)

Tadamichi Shimizu - One of the best experts on this subject based on the ideXlab platform.

  • successful treatment with uva rush hardening in a case of Solar Urticaria
    European Journal of Dermatology, 2014
    Co-Authors: Naoya Mori, Teruhiko Makino, Kotaro Matsui, Yoshiaki Takegami, Shotaro Murayama, Tadamichi Shimizu
    Abstract:

    Solar Urticaria (SU) is a rare idiopathic photodermatosis. The symptoms are usually observed within ten minutes after exposure to sunlight. The action spectra are different among cases, ranging from ultraviolet B (UVB) to visible light [1]. SU is commonly treated with oral antihistamines, sunscreen, plasmapheresis and/or immunosuppressants. Phototherapy with various wavelengths of light and methods has also been performed to induce a tolerant state [2-4]. However, the symptoms of SU are frequently [...]

M Viguier - One of the best experts on this subject based on the ideXlab platform.

  • Solar Urticaria treated with intravenous immunoglobulins
    Journal of The American Academy of Dermatology, 2011
    Co-Authors: H Adamski, A Bonnevalle, P Thomas, M Jeanmougin, C Bedane, J L Peyron, Bernard Rouchouse, F Cambazard, M Viguier
    Abstract:

    Background Solar Urticaria (SU) is a rare idiopathic photodermatosis induced immediately after sun exposure. This disorder may considerably restrict normal daily life and management is extremely difficult when treatment with oral H1 antihistamines and sun avoidance are ineffective. Objective We sought to report the effectiveness of intravenous immunoglobulins (IVIG) in severe SU. Methods We performed a retrospective multicentric study via the mailing of a questionnaire to the French photodermatology units to analyze all cases of patients with SU who were treated with IVIG. Results Seven patients (5 women) with a mean age of 40 years (range 32-55 years) and a mean disease duration of 5 years (range 2-10 years) received IVIG. The administration schedule differed from one patient to another: 1.4 to 2.5 g/kg were infused over 2 to 5 days. Five of 7 patients obtained a complete remission. The number of courses necessary to obtain clinical remission varied from 1 to 3 courses. Complete remission was maintained during 4 to more than 12 months but antihistamines were still required. In one case, psoralen plus ultraviolet A photochemotherapy was administered. Limitations Retrospective study design, limited number of patients, and variations in the IVIG administration schedule could limit the interpretation of the results. Conclusion Our case series suggests a beneficial effect of IVIG in severe SU but additional prospective trials including a larger number of patients are needed to demonstrate the effectiveness of IVIG and to specify the optimal modalities of their administration in this disease.

  • Solar Urticaria successfully treated with intravenous immunoglobulins
    Dermatology, 2009
    Co-Authors: Laurent Maksimovic, Guillemette Fremont, M Jeanmougin, Louis Dubertret, M Viguier
    Abstract:

    Background: Idiopathic Solar Urticaria (SU) is a rare type of physical Urticaria, occurring immediately after exposure to visible or ultraviolet (UV) light. Treatment is based on sun avoidance and on high doses of antihistamines, but is sometimes inefficient. Methods: We report on a 41-year-old patient with severe SU who was successfully treated with a single course of 2 g/kg of intravenous immunoglobulins (IVIG). Results: A dramatic improvement in UVA and UVB tolerance was rapidly observed, with an increase of up to 10 times the UVA minimal Urticarial dose on day 3. The treatment with terfenadine was continued. Healing of photosensitivity was persistent since 100 days after the single course of IVIG, no Urticarian reaction was provoked with polychromatic irradiation rising above 8.3 J/cm2 or after UVA doses rising above 15 J/cm2. Conclusion: Use of IVIG in severe SU can be discussed when high-dose antihistamines are inefficient and quality of life is affected.

Stefan Beissert - One of the best experts on this subject based on the ideXlab platform.

  • uva rush hardening for the treatment of Solar Urticaria
    Journal of The American Academy of Dermatology, 2000
    Co-Authors: Stefan Beissert, Hartmut Stander, T Schwarz
    Abstract:

    Abstract Induction of tolerance by subsequent UV exposures is the most effective therapy for Solar Urticaria; however, it is time-consuming and takes a long time until protection is achieved. Three patients with Solar Urticaria were exposed to multiple UVA irradiations at 1-hour intervals per day. With this rush hardening regimen, protection was achieved within 3 days. (J Am Acad Dermatol 2000;42:1030–2.)